Olav joins ReNeuron with broad commercial experience gained at both major pharmaceutical and small biotechnology companies. He has particular experience of the clinical development, out-licensing, commercialisation and marketing of new therapeutics.
ReNeuron has appointed Olav Hellebø as Chief Executive Officer
Olav joins ReNeuron with broad commercial experience gained at both major pharmaceutical and small biotechnology companies. He has particular experience of the clinical development, out-licensing, commercialisation and marketing of new therapeutics.
Tags
Related posts
- CMT Research Foundation funds study investigating treatment for CMT1X disease
- MPE launches English Myeloma and AL Amyloidosis European Clinical Trial Navigator
- UCL study to assess link between navigation and AD using virtual reality
- New heart disease calculator more accurately predicts patients’ risk of CVDs
- Trial reveals mechanisms that contribute to impact of malnutrition and HIV infection
